DLH Wins Renewal of Clinical Support to NIH-Funded AIDS Clinical Trials Group (ACTG)
Atlanta, Georgia – January 11, 2021 – DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced that it has been awarded a contract to continue operating the AIDS Clinical Trials Group’s (ACTG) Network Coordinating Center (NCC). ACTG, which is funded by the National Institutes of Health, is the world’s largest and longest running HIV clinical trials network, conducting research to improve the treatment of HIV, its co-infections, and its comorbidities. The NCC collaborates with ACTG leadership to provide technical, scientific, and administrative support.
DLH’s award under this contract has an estimated total value of up to $42 million (one base year and six option years). This contract is a subaward to DLH from the ACTG Leadership and Operations Center at the University of California, Los Angeles, which has been funded for the next seven years by NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and collaborating NIH institutes. ACTG was the first clinical trials network to focus on HIV and currently has sites in 15 countries. ACTG often carries out other epidemiological studies and, in 2020, implemented the ACTIV-2 study, a trial to identify effective treatments for early COVID-19.
“DLH is honored to continue its longstanding support of ACTG in its mission to cure HIV and reduce the burden of other emerging infectious diseases,” said DLH President and Chief Executive Officer Zach Parker. “This work combines many of our strengths as a company — managing a consortium of partners, leveraging clinical trials expertise, and developing innovative technology — all in the service of our customer’s vital public health mission.”
“DLH values its relationship with ACTG and is deeply proud of our sustained commitment to this critical public health initiative,” added Jeanine Christian, President of DLH’s Public Health & Scientific Research operating unit.
DLH has managed the NCC since 1987. In this role, DLH staff facilitate the implementation of the network’s scientific research agenda, providing technical and clinical support to ACTG and its community advocates. Responsibilities include protocol development and implementation, site capacity development, and facilitation of network consortium partner collaboration and communications. DLH developed and customized a secure information management system to support the network’s governance, administrative and scientific structure. Named the ‘Network Management Information System’ (MIS), this innovative, web-based information management system was uniquely adapted to support the work of the NCC.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the risk that we will not realize the anticipated benefits of the IBA or any future acquisition; the challenges of managing larger and more widespread operations resulting from the acquisition; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations our recent acquisition and any of future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
Investor Relations:
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com
